Sweet cherries are a rich source of anthocyanins such as cyanidin-3-O-rutinoside, cyanidin-3-O-glucoside, and peonidin-3-O-rutinoside, red pigments with breast cancer chemopreventive properties. Dark sweet cherry extracts have been found to inhibit the growth of both triple negative (ER-/PR-/HER2-) and HER2 overexpressing (HER2+) breast cancer cells.
Now a new study has reported that dark sweet cherry anthocyanins increase the treatment effects of Adriamycin (doxorubicin) chemotherapy in triple negative breast cancer cells. Note that the present study refers to dark red cherries (Prunus avium) that normally can be found in the produce aisle. Tart or sour cherries (Prunus cerasus), which are typically found in jars or juice on store shelves, also incorporate anthocyanins. In addition, they are a superior source of melatonin.
Latest research finds cherry anthocyanins potentiate Adriamycin
The present study was designed to investigate the impact of dark sweet cherry anthocyanins on triple negative breast cancer cells, in particular whether such anthocyanins target Adriamycin drug metabolism and transport in the cells.
To conduct the study, the authors treated groups of 4T1 triple negative cells with dark sweet cherry anthocyanins, Adriamycin, or a combination of both (anthocyanins + Adriamycin). The anthocyanins and Adriamycin were found to inhibit cell viability synergistically. The anthocyanins were demonstrated to modify drug metabolism and transport enzymes, leading to a higher accumulation of Adriamycin in the cells. These effects were confirmed with additional experiments.
The authors conclude that combining dark sweet cherry anthocyanins with Adriamycin has the potential to enhance triple negative treatment by lowering Adriamycin dosage, enhancing its efficacy, and possibly reducing side effects.
Please see our articles on diet during Adriamycin treatment and cherries for more information.